Is Kroger a Buy After Its Latest Earnings Report?

Kroger reported quarterly sales of $34.62 billion, up 2% year over year and near the $34.65 billion consensus, while adjusted EPS of $1.09 modestly exceeded the $1.06 estimate. Adjusted net income declined to $667 million from $695 million, and gross margin was flat at 22.4%, but adjusted e-commerce sales rose 20%. Management cut 2026 identical-sales growth guidance to 0.2%-0.8% from 1%-2%, citing a roughly 140bp pharmacy-sales drag from Inflation Reduction Act adjustments, while maintaining adjusted EPS guidance of $5.10-$5.30 and plans for dividends and buybacks.

Analysis

KR’s maintained EPS outlook despite weaker underlying sales implies that capital allocation, mix, and cost actions—not a demand recovery—are carrying the earnings algorithm. That supports the stock’s defensive floor over the next 1-3 months, but also limits multiple expansion: a grocer generating flat organic revenue generally cannot sustainably grow EPS through buybacks without eventual balance-sheet or reinvestment trade-offs. The critical verification point is whether gross margin holds while transportation and shrink remain elevated; a 20-30 bp margin giveback would matter disproportionately given the low-margin base.

The pharmacy reimbursement reset is more consequential competitively than the headline sales-guide reduction suggests. Larger scaled operators such as WMT and COST can spread pharmacy labor, fulfillment, and digital investment across higher-margin ecosystems, while regional grocers and standalone pharmacies face greater fixed-cost absorption risk. KR’s digital growth is directionally constructive, but without disclosed digital revenue, contribution margin, and fulfillment economics, it should not be capitalized as an incremental profit engine; it could instead be a lower-margin channel mix shift.

Consensus may overvalue the apparent earnings resilience. Maintaining guidance early in a period is less informative than raising it, particularly when EPS can be protected by repurchases and category mix; the next catalyst is evidence that customer traffic and non-pharmacy identical sales are accelerating rather than merely stabilizing. Structurally, the key 6-18 month question is whether KR can convert digital and retail-media/customer-data assets into gross-margin accretion before reimbursement pressure and wage/shrink costs consume the benefit.

Key Decisions for Investors

• Maintain a neutral-to-modest long KR only as a defensive consumer staple position over 1-3 months; do not chase a post-results uptick. Add only if valuation remains at a discount to historical grocery peers and the next update shows non-pharmacy identical-sales improvement with stable gross margin.
• Use a relative-value expression: long KR / short a regional-grocer basket or ETF proxy where available, over 3-6 months. Scale favors KR’s purchasing and pharmacy infrastructure, while smaller chains have less ability to offset reimbursement, labor, and shrink pressure. Exit if KR’s gross margin declines more than 30 bp year over year or sales guidance is cut again.
• Avoid treating e-commerce growth as a standalone bullish catalyst until management discloses penetration, fulfillment cost, and contribution-margin data. Set an earnings-call watch item: evidence of positive incremental digital economics would justify reassessing KR versus WMT; absent that, digital mix may cap margins.
• For downside protection around the next earnings report, consider a limited-risk KR put spread only if implied volatility is below its prior-report range. The adverse case is a further same-store-sales reset combined with margin compression; the upside risk is sustained buyback support and a defensive rotation into staples.